Merck & Co., Inc. (MRK) Earnings Call Transcript & Summary

July 31, 2020

New York Stock Exchange US Health Care Pharmaceuticals earnings 71 min

Earnings Call Speaker Segments

Peter Dannenbaum

executive
#1

Thanks, Laura, and hello everyone. It's great to have you on Merck's call for the second quarter of 2020. Joining me today are Ken Frazier, who serves as our Chairman and Chief Executive Officer; Rob Davis, our Chief Financial Officer; Dr. Roger Perlmutter, President of Merck Research Laboratories; Frank Clyburn, Chief Commercial Officer; and Mike Nally, our Chief Marketing Officer. Before we begin, there are a few things I want to mention. In our GAAP results, you'll notice items like acquisition-related charges and restructuring costs <<inaudible>>, and you should be aware that these have been excluded from our non-GAAP results, with a reconciliation available in our press release. Our press release also includes a table designed to help you follow the sales for the quarter across business units and products. I want to remind everyone that certain statements made on today's call might be viewed as forward-looking statements under the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. These statements reflect the current beliefs of Merck's management and carry significant risks and uncertainties. Should our underlying assumptions turn out to be wrong or uncertainties come to pass, actual results could differ materially from what those forward-looking statements set forth. Our SEC filings, including Item 1A in the 2019 10-K, lay out certain risk factors and cautionary statements that could lead the company's actual results to differ materially from any projections in our forward-looking statements made this morning. Merck has no obligation to publicly update any forward-looking statements. Our SEC filings, today's earnings release and an investor presentation with some highlights of our results are all posted on merck.com. With that, I'd like to turn the call over to Ken.

Ken Frazier

executive
#2

I appreciate that, Peter. Morning, everyone, and thanks for being on the call today. First off, I'd like to express gratitude to every employee across the globe who showed resilience and diligence during this hard period. Thanks to their unrelenting efforts, we keep moving forward on our strategic priorities, and we finished the quarter with business momentum that is picking up. The pandemic has created obstacles that hardly any of us could have envisioned even half a year back, yet it has likewise shown how vital organizations dedicated to pathbreaking science truly are. Our scientists are intensely committed to this work, and this mission gives us enormous energy. To put it plainly, this is the reason Merck exists. All through the quarter, Merck performed well, both operationally in backing our current portfolio and by pushing forward our innovative research program. We keep operating at an extremely high standard, with no major interruption to the manufacturing, supply and distribution of our medicines, vaccines and animal health products, nor to our clinical trials. As anticipated, social distancing measures across many areas hurt second quarter volume for a number of our products; even so, patient access to care is improving steadily, including for our vaccines portfolio, which took a particularly severe hit during this quarter. We stay confident that our innovative portfolio will generate robust, long-term growth. Our financial strength likewise enables us to carry out our capital allocation priorities, such as continuing to put money into internal R&D and business development. Beyond moving our strategic priority forward, we also made substantial headway on our plans to spin off Organon & Co., which is still on schedule to wrap up in the first half of 2021. We continue to believe that forming two more focused companies will leave each one stronger and better positioned within a changing healthcare landscape, which will help the patients we serve along with our shareholders. We recently revealed the appointment of a number of gifted and seasoned leaders from outside the company to our strong leadership team. They are already heavily involved in pushing the various work streams now in progress to prepare the standalone company for success. Before Roger gives you more specifics, I want to offer a few remarks about the many efforts now underway at Merck on the COVID-19 front. COVID-19 poses an enormous challenge for the biopharmaceutical research community. And Merck is acting urgently to bring our deep expertise in vaccines and infectious diseases to bear on possible solutions. During the quarter, we announced two vaccine development efforts, one via a collaboration with IAVI and the other via a now completed acquisition of Themis; we chose these candidates since they rest on proven platforms that we expect will yield a safe, effective and broadly deployable vaccine with the promise of single dosage. Both vaccine candidates will enter the clinic soon, and we have started investing to enable our ability to manufacture hundreds of millions of doses. We also announced a program to develop a novel, orally available, antiviral candidate through a collaboration with Ridgeback Bio. This drug candidate has moved forward into a Phase 2 clinical trial. We feel good about what lies ahead for these three programs, and should they pan out, Merck has pledged to collaborate with partners in order to deliver wide-reaching, reasonably priced, and fair access around the world. These initiatives demonstrate how we keep building on our in-house strengths by bringing in cutting-edge science projects from outside. Roger is going to share additional specifics regarding the notable strides being made in our research work in other areas. On a larger scale, the way the biopharmaceutical sector has answered COVID-19 has been remarkable. No other industry is as well placed as ours to take on this public health crisis across the globe. Success will depend on cooperation spanning the scientific community, public health, and the biopharmaceutical sector, and on making sure we are properly ready for whatever comes next. We have faith that science will in the end win out against COVID-19 through novel treatments and vaccines. To wrap up, let me voice our thanks to frontline healthcare personnel and to our own team members, who have put in effort to support patients impacted by COVID-19. The devotion they show motivates us and strengthens our resolve to deliver new instruments that can help bring this pandemic to a close. This crisis highlights how much our industry matters to society, and also how necessary it is for businesses such as Merck to keep putting money into research and development so we can tackle the biggest health dangers, both at present and going forward. With that said, I'll hand things over to my colleague, Rob Davis, who will walk through the specifics of our results and our guidance.

Rob Davis

executive
#3

Thank you, Ken, and hello everybody on this call. Like Ken pointed out, our company delivered solid results amid a situation unlike anything we've seen, even though the COVID pandemic left a notable mark during the quarter—especially across April and May—the overall business held up fine. Over in human health, the hit came in roughly as we had anticipated, whereas animal health saw a smaller blow than we had forecast. Even so, we managed to post results exceeding expectations in both human health and animal health, thanks to fundamental operational resilience paired with how we executed while the pandemic unfolded. Given how we've been able to generate better and quickening operational traction, our outlook now calls for a stronger showing during the back half of the year. To put things in perspective, stripping out COVID's effect for the quarter, Merck's sales growth at the underlying level would have come in at 6% on a nominal basis and 9% when exchange is excluded, which speaks to robust demand across our key growth pillars. We keep operating from a place of financial and operational strength, and that let us carry out our capital allocation priorities. Spending behind our broad pipeline of research programs stayed strong, and we likewise wrapped up two collaborations plus one acquisition, bringing promising vaccine and antiviral candidates in-house to tackle the COVID-19 pandemic, just as Ken mentioned. Everything here serves our aim of pushing science forward to meet unmet medical needs—the heart of Merck's mission. Now let's move to our second quarter results. Revenue for the whole company came to $10.9 billion, down 8% versus a year ago, or 5% once you set aside the drag from foreign currency. COVID-19 took $1.6 billion off our second quarter results, which breaks down as roughly $1.5 billion within human health and about $100 million within animal health; on the human health side, the sales hit landed unevenly across our vaccines, hospitals, women's health and oncology products, driven by access restrictions stemming from social distancing orders along with hospitals and resources being prioritized for coronavirus patients. On the animal health side, livestock product sales felt pressure from shifting protein demand amid restaurant closures and regional outbreaks, while companion animal product sales mirrored fewer visits to veterinarian offices; worth pointing out is that despite these near term headwinds during the quarter, the fundamental strength of and demand for our products drove first half growth of 4% excluding exchange. The rest of what I'll say centers on how our key growth drivers performed at the underlying level plus near term trends, and it will be on an exchange basis. Human health revenues for us fell 6%. In oncology, KEYTRUDA sales climbed 31% versus a year ago, hitting $3.4 billion for the quarter; here in the U.S., KEYTRUDA showed robust growth across every key tumor type. We keep reinforcing our IO leadership, including in lung, even with recent competitor launches; gains came from ongoing strength in melanoma, bladder, and head and neck cancers along with solid momentum from launches in renal cell and in the matriarchal carcinomas. We got FDA clearance for a six-week dosing schedule covering every adult indication, and that opened up broader patient access while also helping drive growth. Beyond the United States, the lung cancer indications are still a key factor behind KEYTRUDA's expansion. Within the EU, momentum keeps coming from adoption of KEYNOTE-189, with reimbursement now locked in across every major market; in Japan, a combination of factors — postponed starts for new patients, less frequent dosing for existing ones, and substantial seller price changes in February and April — outweighed by more than the volume gains from new indications. COVID-related effects on KEYTRUDA showed up during April and May across every tumor type, though not as severely as we had anticipated; we took encouragement from the rebounds observed in June, especially within the United States and Europe; and that pattern has carried into the third quarter. Robust increases for Lynparza and selumetinib keep strengthening our oncology results, since both drugs saw only limited pandemic disruption this quarter's performance still mirrors expansion and leadership within the PARP category in the United States, and the recent introductions of PAOLA-1 for ovarian cancer and PROfound for prostate cancer create chances for growth ahead. Lenvima holds market leadership in first line hepatocellular carcinoma, and its pairing with KEYTRUDA and endometrial carcinoma has become the top treatment regimen for the second line setting in the United States. Now shifting to vaccines, our vaccines portfolio took a negative hit from fewer patient visits to physicians' offices, which matched what we had expected. GARDASIL sales fell 24% year-over-year, due to stay-at-home workers in the United States and most European markets, partly balanced out by sustained demand from core strength in China; within the United States, we were pleased to observe a notable rise in wellness visits starting in late April for children and late June for adults, and we expect that pattern to bring about a recovery for our vaccines business during the back half of the year. Our hospital business faced disruption from postponed and canceled elective surgeries plus hospitals prioritizing coronavirus patients. That hurt sales of BRIDION, which dropped 18% year-over-year. Lower wholesale or inventories also played a part in that decline. We stay confident about underlying demand for BRIDION and are heartened by the continuing recovery in overall surgical procedure volumes. Partly counterbalancing the drop in our hospital portfolio was growth in provames. Animal health revenue rose 3% this quarter, reaching $1.1 billion. Livestock climbed 3% thanks to contributions from an acquisition within our animal health intelligence product line. And companion animal likewise rose 3%, reflecting strong growth at the productive line of products. Visits to veterinarian offices were hurt early in the quarter, but offices reopened sooner than anticipated, which helped volumes. Moving to the rest of our P&L, my remarks will be on a non-GAAP basis. Gross margin came in at 73.8% for the quarter, a decrease of 160, driven mostly by catch up amortization for expected milestone achievements tied to our collaborations on Lynparza and selumetinib. Operating costs fell 9% compared with the same period last year, landing at $4.4 billion. All told, COVID led to roughly $325 million less in spending, mostly because of reduced promotional, selling and administrative costs, plus smaller laboratory, travel and meeting expenses. The big jump in other income versus a year ago came from unrealized equity gains on our security holdings, mainly our investments in Moderna and MGM. A 15% tax rate for the quarter reflected a lower full year effective tax rate stemming from a favorable earnings mix. Put together, we earned $1.37 cents per share, up 9% excluding exchange. Now, on to our outlook for the rest of the year. April, as anticipated, proved a notably difficult month in the human health business. But as we progressed through May and especially June, we observed a substantial rise in patient wellness business to providers and in elective surgeries of hospitals; and our oncology business held up especially well thanks to the strength and breadth of our offerings. Conditions have clearly gotten better, and even with more outbreaks and higher infection rates affecting the phasing of our recovery, we think the healthcare system is in a stronger position to deliver patient access as we go through the balance of the year.

Rob Davis

executive
#4

What we're seeing is better fundamental operating performance in a number of areas of our portfolio, and that should more than compensate for the COVID-19 hit while driving stronger growth in the back half than we had expected. On top of that, we had the advantage of earlier spending on digital tools that let us engage with patients, providers and payors, so we could keep handling medical questions and keep promoting our products well. That makes us even more confident about generating efficiencies in the business as we adjust to a world after COVID-19 via our ongoing digital and other transformation work. Over in Animal Health, as I noted, vet clinics reopened sooner than we first thought, which is good for our companion animal lineup, and stay-at-home orders were relaxed ahead of schedule, which helps our livestock products. Those positive dynamics drove second quarter results that beat what we expected and gave a lift to our full-year outlook. We'll keep tracking regional flare-ups, how restaurants and schools reopen, and whatever effects might hit demand for livestock products. Moving to guidance, the update we've provided shows ongoing confidence in the fundamental strength of our business, a smaller COVID drag, the previously anticipated <<inaudible>> business overall, and a better currency backdrop. Our thinking on how the COVID impact will play out has not changed. We're assuming the heaviest COVID hit came in the second quarter, that no recovery had started yet during the second quarter and it will carry into the third quarter, then operating levels get back to normal in the fourth quarter. We now see revenues between $47.2 billion and $48.7 billion, an $850 million bump over our earlier midpoint. Guidance now captures about $1.95 billion in COVID headwind for the year. That's down from the $2.1 billion we assumed before, with human health about in line and animal health under our earlier estimates. We're now assuming foreign exchange drags results by about 2 percentage points based on mid-July rates. Taken together, guidance points to 3% to 6% revenue growth for the full year, stripping out currency effects, which speaks to robust underlying demand for what we sell. The single spot we're monitoring is vaccines, and GARDASIL specifically, for a possible longer recovery period. Still, that risk is completely baked into our guidance range and more than made up for by the strength we anticipate elsewhere in the portfolio. Gross margin, we still expect, will come in around 75%. Operating expenses should now be about level with last year, as higher R&D spending is offset by lower SG&A costs. The bump in our OpEx assumptions compared with earlier guidance comes from R&D tied to speeding up our COVID-19 programs. Even so, this guidance continues to imply operating margin expansion of roughly 100 basis points this year. For the full year, we now anticipate a tax rate between 16% and 16.5%, which mirrors a better earnings mix. At this point, we anticipate other income to come in at approximately $550 million, prior to my ability to record unrealized gains from our equity securities portfolio, which are based on valuations as of June 30th. Our expectation for shares outstanding remains 2.54 billion. When we put these pieces together, our non-GAAP EPS is now projected to land somewhere between $5.63 and $5.78, and that represents a $0.44 lift from where the midpoint previously sat. Within this guidance range, there is an adverse effect from foreign exchange of about 3 percentage points. An improved tax rate along with greater other income stemming from gains on our equity holdings are providing a boost to our results. Setting those advantages aside, though, we keep generating operational leverage within the P&L. Growth in revenue, paired with ongoing expense discipline, even as we put money into R&D — including our COVID-19 candidates — and expand capacity, should push operating margin expansion through the entire year. Both our ability to generate cash flow and our access to capital remain robust, and we are still well positioned to proceed with our capital allocation priorities, which include fully investing behind our key growth drivers and pipeline. That means a sustained dedication to the dividend as well as strategic value-enhancing business development aimed at strengthening our pipeline and long-term growth potential. In closing, we stayed confident about the business's fundamentals and the significant growth opportunities that lie ahead, even with the near-term effects of the pandemic. The favorable recovery pattern observed throughout the quarter puts our company in a position to accelerate business momentum as we move into the latter half of the year. The fundamental health of the business, along with demand for our innovative portfolio of medicines and vaccines, is still strong; when combined with our robust clinical execution across the portfolio and our growing indications — which Roger will discuss shortly — this keeps reinforcing our confidence in both the sustainability and the strength of our revenue growth. Amid these difficult times, we are drawing on our operational and financial strength, not merely to get through the storm, but also to deliver meaningfully on our innovation strategy and our mission of bringing new medicines to patients. It remains our belief that this puts Merck in the best position for success and value creation well into the future. With that said, I would now like to hand the call over to Roger.

Roger Perlmutter

executive
#5

Thanks, Rob. In Q2, we managed to broaden our lab activities past the critical output of supplies needed for clinical trials, which means we're now again picking novel chemical entities in discovery work and moving those materials forward into preclinical evaluation. With our labs back up and running, our top concern is still keeping our workforce safe; next comes making sure participants enrolled in our trials get their therapies and proper care; and last, we're back to using our expertise to uncover fresh drugs and vaccines. Quite a few of the initiatives I mentioned when I spoke on our Q1 earnings call have moved ahead significantly. To illustrate, in May we obtained FDA clearance for Lynparza, which we created alongside our partners at AstraZeneca, for use together with bevacizumab as first-line maintenance therapy for adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who achieved a complete or partial response to first-line platinum-based chemotherapy and whose tumors show homologous recombination deficiency according to an FDA approved diagnostic test; that clearance drew on a biomarker subgroup analysis from the Phase 3 PAOLA-1 trial, where Lynparza plus bevacizumab extended median progression-free survival by over two times, reaching 37.2 months. Lynparza likewise got FDA clearance in May to treat patients with metastatic castration-resistant prostate cancer whose tumors have worsened after earlier treatment with enzalutamide or abiraterone and additionally carry deleterious or suspected deleterious germline or somatic homologous recombination repair gene mutations; that clearance rested on findings from our Phase 3 PROfound study; we figure that roughly 20% to 30% of men with metastatic castrate resistant prostate cancer have tumors harboring such mutations. Later that quarter, Lynparza secured a positive opinion from the CHMP for first-line maintenance treatment of patients with metastatic pancreatic cancer whose tumors carry germline BRCA mutations, drawing on the POLO study. The European commission endorsed that recommendation early in July. KEYTRUDA saw many significant regulatory developments during the second quarter, to the point that the FDA label now runs close to 100 pages and lists almost 30 explicit approvals. I won't go through every regulatory action tied to KEYTRUDA filings today, but we will point out that the second quarter opened with FDA approval of an extended dosing interval, 400 milligrams every six weeks for all adult indications. Although this new dosing schedule was already registered in Europe, its approval in the United States gives physicians and patients options to cut down on the number of clinic visits they need to make at a moment when they have put important social distancing measures in place. In June, the FDA handed down three further approvals for KEYTRUDA. First, for treating recurrent or metastatic cutaneous squamous cell carcinoma that can't be cured through surgery or radiation therapy. Next, it's for the initial therapy of individuals suffering from unresectable or metastatic colorectal cancer whose tumors demonstrate mismatch repair deficiency or are MSI-high; and then thirdly, it's for the second-line therapy of grown-ups and children with unresectable or metastatic solid tumors that have worsened after earlier treatment and who lack satisfactory options, as long as those tumors display a high mutational burden — no fewer than 10 mutations for each megabase of DNA. I want to point out that this marks the second tumor-agnostic indication for KEYTRUDA. Back in 2017, we obtained the very first indication of this kind in the entire history of oncology therapeutics, through accelerated approval of our MSI-high indication for KEYTRUDA in grown-ups with solid tumors. As I noted a moment ago, this strategy was broadened even more in June, when we gained approval for initial therapy of MSI-high colorectal cancer, drawing on our KEYNOTE-177 trial. The FDA's clearance for second-line therapy of patients whose tumors exhibit a high tumor mutational burden is the second occasion KEYTRUDA has earned an indication grounded in the molecular features of the tumors themselves, instead of the cell or organ thought to be their origin. Two additional FDA approvals from the second quarter warrant particular attention. GARDASIL 9 won approval to prevent Human Papillomavirus related oropharyngeal and other head and neck cancers. That was an accelerated approval, resting on how well GARDASIL 9 prevents Papillomavirus-related anogenital disease, and backed by studies demonstrating clearance of persistent oropharyngeal HPV infection index needs. A recent analysis from the U.S. centers for disease control showed that HPV attributable oropharyngeal cancer has now moved ahead of cervical cancer to become the most prevalent form of HPV related cancer across the United States. Approval in the head and neck cancer setting came about after decades of investigation carried out by Merck Research Laboratories. We also secured FDA approval for RECARBRIO to treat hospital-acquired and ventilator-associated bacterial pneumonia brought on by susceptible organisms. As COVID-19 hospitalizations rise, the danger of secondary bacterial pneumonia grows more serious. RECARBRIO delivers an important new antibiotic that may be especially useful for treating infections caused by pseudomonas species. Past these regulatory approvals, we keep supporting — keep submitting important new files. For instance, in the second quarter we filed results from the VICTORIA study run alongside Bayer, which showed that vericiguat, our novel orally administered soluble guanylate cyclase activator, lowered the risk of cardiovascular death and heart failure hospitalization when added to standard therapy in patients with symptomatic chronic heart failure following a worsening event. Those data had earlier been presented at the American College of cardiology meetings in the spring. This application has received priority review from the FDA, which speaks to the considerable unmet need for fresh treatment options among heart failure patients. Over in oncology, we likewise filed for review our data from the KEYNOTE-355 and KEYNOTE-522 trials, and those document how KEYTRUDA performs in triple negative breast cancer — both as a second line therapy given alongside chemotherapy, which is the KEYNOTE-355 situation, and as an addition to surgery within the neoadjuvant setting together with chemotherapy followed by monotherapy, with KEYTRUDA given in the adjuvant setting, that being the KEYNOTE-522 study. Yesterday we told you both files had been accepted for FDA review, and in this case as well the KEYNOTE-355 file received priority review. This week we further announced that breakthrough designation had been given by the FDA to MK-6482, our novel HIF-2 alpha inhibitor, for treating certain patients who have von Hippel-Lindau disease associated renal cell carcinoma, drawing on data we presented at the American Society for Clinical Oncology meetings in June. Lastly, our extensive range of activities across cardiovascular medicine, oncology and infectious diseases has grown to include three new programs aimed at interdicting the COVID-19 pandemic. As you know, in the second quarter we formed a partnership with Ridgeback Biotherapeutics to develop MK-4482, a nucleoside analog that interferes with faithful replication of the SARS-CoV-2 viral genome. MK-4482 has by now been examined in an ascending dose protocol and was shown to be well tolerated across five-day oral administration, reaching drug levels we would anticipate would be more than sufficient to block viral replication.

Roger Perlmutter

executive
#6

Right now, this compound is being evaluated in three separate Phase 2 programs for outpatients, and also for inpatients in both the United States and the United Kingdom. Drawing in part from what those studies show, we anticipate kicking off two sizable pivotal trials starting in September — one among outpatients, the other among patients hospitalized with COVID-19. Beyond that, talks are underway with the active consortium about launching a big Phase 2 outpatient study that would run under the National Institute of Allergy and Infectious Diseases' oversight. When examined in vitro, MK-4482 has shown a robust resistance barrier, something we would have anticipated given how it works. Take, for instance, its activity against viruses that picked up mutations making them resistant to remdesivir. Given how enormous the medical need is for an oral treatment that can lessen COVID-19's toll, we've built the highly aggressive clinical program I just outlined. And we've locked in manufacturing capacity sufficient to make many millions of doses of this drug prior to the close of this year. Simultaneously, we're pursuing two significant new vaccines aimed at SARS-CoV-2. As Ken noted, three reasons drove the selection of these vaccine approaches. To start, they rely on vaccine platforms with a proven track record, ones already used in human studies that showed both efficacy and safety. Next, because they are replicating viral vaccines, they deliver a highly potent immune stimulus, which holds out the possibility of administration as just a single dose. When confronting an aggressive disease that has spread across the globe like COVID-19, our view is that lowering the obstacle to vaccination as far as we can is the sensible course. That could mean, for instance, introducing a vaccine that works with only one administration. Third, because we think different populations may very well require different vaccines, we picked two vaccine platforms that are well characterized yet differ considerably in their properties. One is a measles virus recombinant created by the Institut Pasteur in Paris, which came to us via our acquisition of Themis Bioscience, and the other is a vesicular stomatitis virus recombinant originally developed by Health Canada, which we're moving forward with alongside the International AIDS Vaccine Initiative, IAVI. That construct draws on the very same virus platform we used for our successful Ebola virus vaccine, which got registered in the United States earlier this year. In preclinical work, both COVID-19 vaccine constructs have now been found to trigger neutralizing antibody production after a single intramuscular administration. Our effort using the measles virus vaccine platform, known as V591, has not yet finished clinical manufacturing. Later this quarter, we intend to launch clinical studies carried out together with the Institut Pasteur. In the meantime, we've been producing clinical doses of the VSV-based COVID-19 vaccine, called V590, at our Pennsylvania facilities. With V590, we likewise expect clinical studies to get underway within the next few months. Preparations for large global clinical trials covering both V590 and V591 are now almost finished. Those studies are going to start once we've got data that supports immunogenicity. And then, one more plus for V590: it might work if given by mouth using a swish-and-swallow approach. That, in turn, could bring down the obstacle to vaccination if it turns out to be effective. It should be noted that Merck Research Laboratories keeps pushing forward with new drugs and vaccines on a number of fronts. Along those lines, I want to give particular recognition to the commitment of over 10,000 MRL staff members worldwide, whose efforts beyond what is required have once more given us hope that the world can achieve more freedom from serious disease. Looking at how far we've come with MK-4482 and with both of our COVID-19 vaccines, I feel confident that we can lessen the toll of this terrible pandemic. With that, I'll hand the call back over to Peter.

Peter Dannenbaum

executive
#7

Eric, would you please set up the order for Q&A? And let me remind those asking questions to keep it to 1 or 2 questions, as usual. There are many questioners waiting, and we're ready to run a little past 9 to reach as many as possible. Some of our speakers are remote today; so when those questions arrive, I'll quarterback them as best I can. Laura.

Andrew Baum

analyst
#8

Thanks. I have two things to ask. To start, your clinical trials show that cold expansion is happening substantially across multiple programs, including one that has already been withdrawn, plus a small <<inaudible>> and several more, which tells us you are observing signals of encouraging activity. Since the market pays such close attention to how much KEYTRUDA matters, could you tell us when you might come forward to disclose some of that maturing Phase II information and broaden into cardiology too? That is my first question — the timing for sharing it. I realize you won't tell me the level of confidence or the date, but please give whatever you can. Second, because KEYTRUDA is seen as competitive, especially in non-small cell, you have a trial currently running that uses Lynparza for maintenance. So maybe, Roger, you could speak to how hopeful you feel about that, since you are clearly pursuing it in other indications for sensitive disease, and in particular whether you could speak to — do you believe selection is needed for patients whose HIV genes are <<inaudible>> lost, or do you think it simply comes down to <<inaudible>> combining it with the sales, which are <<inaudible>> adequate? Those are my two questions. Thank you.

Peter Dannenbaum

executive
#9

Roger, I believe both of those are directed at you. If you...

Roger Perlmutter

executive
#10

Absolutely, Andrew — I appreciate those questions. If I understood them correctly, they're connected in a way, and I should apologize for being remote, since the connection may not be as crisp as I'd prefer. Still, when it comes to broadening the clinical trial work across a wide range of novel agents, we are observing some compelling developments. We're hopeful that a portion of this information can be shared at the European Society for Medical Oncology Meetings taking place in September, and we expect further chances toward the close of the year to discuss it. These findings speak directly to the matter you brought up regarding non-small cell lung cancer. To begin, I want to note that, as you're aware, our dataset in non-small cell lung cancer is exceptionally robust. KEYTRUDA performs very well in that context, and it performs well alongside chemotherapy, as we have demonstrated. That continues to be an enormously significant approach — the leading approach for treating non-small cell lung cancer, whether given alone in the PD-L1 high group or given together with other therapy. With that said, you're likewise examining how these novel agents act against a broad array of distinct checkpoints across numerous cellular components, while also exploring the question of mismatch repair deficiency together with KEYTRUDA. We feel optimistic that we'll be able to further separate non-small cell lung cancer patients based on the underlying characteristics of their tumors, and that ties directly to our work involving MSI-high and tumor mutational burden so we can deliver even stronger outcomes in the non-small cell lung cancer setting. So in short, we are highly engaged in this space, producing a great deal of fascinating data, and we hope to present it to you before long.

Peter Dannenbaum

executive
#11

Thanks. Laura, let's take the next question.

Umer Raffat

analyst
#12

I appreciate it. I'd like to ask about COVID, and I have two parts to that, if that's alright. Roger, by now you've likely seen quite a bit of the initial round of data on COVID vaccines; and without offering any opinion on a specific company, I'd be interested to hear how you look at the data and the overall picture so far from all the clinical data on COVID vaccines? Maybe in particular, do you believe the neutralizing titers that the different layers have reported are sufficient? Or do you see considerable space for improvement, and what's your view on the T-cell data? And then regarding your small molecule for COVID, do you believe an antiviral benefit can be demonstrated? Since that is something Remdesivir could never accomplish. Yet there's also this line of thinking that large viremia doesn't occur in COVID, or perhaps you can't demonstrate that at all. So I'd really value your perspective on that.

Peter Dannenbaum

executive
#13

Roger?

Roger Perlmutter

executive
#14

Absolutely, Umer. To begin with, regarding the data on the COVID vaccine, we need to acknowledge that our initial understanding of SARS-CoV-2 was extremely limited at the outset. What we've observed so far from various early trials—Phase I studies—is honestly as promising as anyone could expect. There was no assurance that the spike protein of SARS-CoV-2 would turn out to be this immunogenic. So, broadly speaking, immune responses across the vaccinated population are quite strong. Your question is whether there's sufficient neutralizing antibody and how well it will perform clinically. Unfortunately, we can't truly determine that until we examine Phase III trials. But I suppose I'd say first that, as others have mentioned, most vaccines appear likely to need a boost to achieve high-titer neutralizing activity against the spike protein. That much seems evident. We don't know for certain, and perhaps outcomes will be better, which we all hope for. Over time, we'll learn more. The second issue, obviously, is whether generating an immune response to the spike protein alone is enough. Or do we also need responses against other viral components, especially the nuclear protein? Then, naturally, there's the matter of what role T cell immunity plays, and that ties somewhat into what we're ultimately aiming to accomplish. Lastly, lingering in the background is whether the immune stimulation we're inducing might actually lead to adverse effects, since it's widely thought that the severe lung complications from SARS-CoV-2 infection involve an excessive immune reaction causing tissue damage. So all these remain unresolved questions, answerable only through extensive Phase 3 trials lasting a significant duration. Those trials have at least started in a few instances now. More will launch shortly. And we'll get to observe precisely how these vaccines perform. Right now, I don't believe we can predict it, other than to note it's definitely a positive sign that the spike protein in its multiple forms—usually as a prefusion form, or hopefully so—appears highly immunogenic, with decent antibody titers generated; that ought to give us substantial optimism. I should add, I—we—the wider industry is working together and considering these challenges on how to produce enough doses. And I think everyone should feel greatly heartened by the vast quantities of vaccine doses being planned for manufacturing, especially as we move into 2021 and later. Assuming these shots do what they're supposed to, my sense is that ultimately the sector will be capable of manufacturing sufficient supply to vaccinate a sizable share of people across the globe.

Peter Dannenbaum

executive
#15

Roger. I think there is a second question on 4482.

Roger Perlmutter

executive
#16

Okay, so the next question is whether MK-4482 would give us an antiviral advantage. What matters to note here is that MK-4482's mechanism is quite different from Remdesivir's. Remdesivir, as we know, works as an RNA-dependent polymerase inhibitor. It brought about determination. MK-4482, on the other hand, is a cytosine analog that gets incorporated, and because of that, it leads to misincorporation of bases into the nascent RNA. Those RNAs do get produced, but they carry a great many errors, and what results is known as aero catastrophe, which is an extremely potent way of stopping the creation of functional virus; so those represent two rather distinct mechanisms. What we expect is that virus would still be produced for at least some period, yet that virus would be unable to replicate. Based on, from, various in-vitro studies, one can measure a dramatic drop in virus production. And perhaps we'll observe the same in our clinical studies. Naturally, we are watching for it. The Phase 2 studies are ongoing. So it won't be very long before we get an opportunity to see that. We are, naturally, also measuring clinical outcomes.

Umer Raffat

analyst
#17

Thank you very much.

Peter Dannenbaum

executive
#18

Thank you, Umer.

Terence Flynn

analyst
#19

Great, thanks. I might have a couple here. First, a follow-up regarding the oral antiviral for COVID2. I'm curious whether you could say something about when we should anticipate seeing part of the initial Phase II data, and then what your definition of success looks like there. My second question is for Rob. I'm just wondering what the outlook is for capital allocation over the remainder of the year if the share program remains paused. And does that mean you plan to be more active when it comes to business development in the near term? Thank you.

Peter Dannenbaum

executive
#20

Roger?

Roger Perlmutter

executive
#21

Okay, regarding MK-4482 — honestly, I'd rather not release bits and pieces of information about this one. Once we get solid results from the Phase II program, we'll certainly share them with you. But I want to mention that we'll likely be starting very large pivotal trials in September. Those will be the ones that really matter. The aim here must be that with this drug, which is active when taken orally, we can shorten how long symptoms last, and even more crucially, prevent people who have symptoms from getting so ill that they need hospitalization, or if they are hospitalized, that they need to be in an intensive care unit. What's encouraging about MK-4482 is that since it's an oral medication taken as capsules, it's simple to give from the moment symptoms appear. That, I believe, could translate into a significant impact on clinical outcomes. And that, naturally, has to be what treatment is trying to achieve.

Peter Dannenbaum

executive
#22

And Rob, turning to how we're deploying capital.

Rob Davis

executive
#23

Yeah. Hello. So, like you mentioned, we halted the buyback program following Q1, and that decision was really made just to be extra careful since we couldn't predict how things would unfold. I'm glad to say — and I noted this during my prepared remarks — that our cash flow is still quite robust. And our ability to access capital is quite robust too. I believe we showed that recently with a debt offering at historically low rates. So given that, we're sitting in a solid spot. When it comes to buybacks for the rest of the year, we keep assessing that option. Business development matters a great deal to us. So clearly, my priority is ensuring we've got the capital needed for business development, for funding the business itself, for the significant capital expansion currently in progress, plus all those key programs we've discussed. So we're reviewing everything and will keep weighing whether we'll begin again at some point in the rest of the year.

Peter Dannenbaum

executive
#24

Thank you, Terence. Next question please, Laura.

Louise Chen

analyst
#25

Hello, and thank you for allowing me to ask. My first inquiry is this: given the pandemic and with the 2020 presidential election approaching, what did the M&A landscape look like? What about valuations? And how willing are sellers? Then my second question: if V114 and the remainder of your PCV portfolio get approved, where does Merck fit within the PCV treatment paradigm? Is it a winner-take-all market? And would that shift if these PCV24 actually reach the market? Thank you.

Ken Frazier

executive
#26

Louise, let me begin with the business development piece. I appreciate the question. Like Rob mentioned, business development continues to be a very significant priority for us at present and into the future. At this moment, I'd say the climate we find ourselves in remains a difficult one, because when you examine the first half of the year, the Biotech IPO market has run ahead of last year, in spite of every difficulty tied to COVID, in spite of every worry that could arise regarding the election. And naturally, established biotech has turned in a strong performance this year as well. Therefore, I believe our challenge lies in locating the finest scientific capability in a manner that generates value for our shareholders; and at this point, I'd say seller expectations are quite elevated, regardless of the matters surrounding the political landscape, the executive orders and all the rest; so ultimately, we must keep hunting for the best clients in line with the requirement to build value for our shareholders. And in my view, the election is not a crucial factor in that.

Peter Dannenbaum

executive
#27

And Mike Nally, do you want to report.

Mike Nally

executive
#28

Hey Louise. Regarding V114, the key point is that any upcoming PCV vaccine must, above all, keep preventing infection — or rather keep producing an immune reaction — against each of the 13 serotypes that are shared with the current PCV13 shot, and afterward include extra serotypes. With V114, we've managed to accomplish exactly that quite effectively among both adults and children. Going ahead, we believe the PCV sector can accommodate several choices. Consider the rotavirus space as a solid comparison: even though the profiles and coverage differ, we essentially have a divided market between Rotarix and Rotateq. So moving forward, we see a substantial unmet need developing in this area. V114 should be a central player in addressing it, and we'll keep exploring other possibilities down the road, including V116 and V117.

Peter Dannenbaum

executive
#29

Thank you, Louise. Next question please, Laura.

David Risinger

analyst
#30

Yeah, many thanks. I've got a pair of things to ask Roger, if I may. To start with, when it comes to the Ridgeback Bio oral antiviral, how do you see the immunogenicity risk? Also, what's your approach for showing the FDA that the drug's action comes with safety that's acceptable? Then, secondly, Merck possesses a highly advanced grasp of mRNA vaccines. Would you explain the reasoning behind Merck's decision against mRNA vaccine development for COVID? I realize you mentioned this briefly, yet a bit more detail would be useful. And out of the two Merck candidates, could you point out the one deserving more of our attention? Thanks.

Peter Dannenbaum

executive
#31

Roger?

Roger Perlmutter

executive
#32

Okay, thanks David. To start with, regarding MK-4482, as you're aware, this compound tests positive for Ames, which is somewhat expected because of how it works — it's a cytosine analog. So you'd anticipate that kind of result. What matters is whether it has mutagenic effects that are significant in mammalian cells, and how we should handle that. Normally, we wouldn't want to advance mutagens into clinical use, though that has happened when the benefit-risk balance is justified. Regarding this particular compound, it's worth pointing out that in other assays, such as the in vitro and in vivo micronucleus tests, it comes back negative. Additional in vivo mutagenesis tests in mammalian systems are underway. We'll also perform the standard preclinical assessments typical in these situations, including reproductive toxicology work and, naturally, accelerated rodent carcinogenicity studies; these are the customary steps, and I expect that when all the data are considered together, the benefit-risk profile for a short-term regimen treating an acute pulmonary infection will turn out favorable; and naturally, that's been observed previously. So this is something we monitor closely. Yet at the same time, I believe it's something we can surmount. As for MRNA vaccines, you're correct that we possess considerable experience, acquired through collaboration with our partners at Moderna, in examining MRA vaccination. I believe there are notable advantages to MRA vaccination specifically, particularly its speed, as both Moderna and Beyontec, now collaborating with Pfizer, have shown — one can go rapidly from identifying the sequence, the genetic sequence of a potential target, to creating an immunogen. Conversely, our worry from the outset was that this would become a pandemic. We thought so well before WHO labeled it one. We never imagined it would be this severe or this widely spread as it has turned out to be; it poses a danger to the whole globe. And as the saying goes, nobody is safe until everyone is safe; keeping that in mind, there will be a need to provide effective vaccination for a substantial portion of the human population. Several elements of that deserve emphasis. First, naturally, as I mentioned, having a single-dose vaccine is desirable. It would also be beneficial to have a vaccine that could be given orally, similar to how — not that this is directly comparable — the oral vaccine eventually supplanted the original polio vaccine. Moreover, we must acknowledge that numerous distinct groups are affected by the infection. Naturally, in the end everybody gets infected, yet our older adults face a very elevated danger, especially anyone dealing with cardiovascular disease beneath the surface. Plus, that older group generally doesn't mount as strong a response. Given that situation, and particularly with a potent immunogen, this was one motive for selecting a replicating viral platform, alongside our wish for a single dose; we also have kids, teens, and people in their twenties who right now are getting infected in huge numbers. And many individuals in strong, early adulthood are landing in the ICU. Such people mount very powerful immune responses, yet it matters to achieve neutralization fairly quickly, I think, within that group; so that might call for a distinct type of virus, perhaps not the identical one you'd deploy among adults, as a vaccine, a separate sort of viral vaccine. As for which of these deserves our focus, I believe I'm focused on both. Information will arrive sooner from the measles platform. And naturally, that measles platform—the measles vaccine—has been given successfully to billions of individuals; thus we hold considerable trust in how it will act. We simply require immunogenicity data. Pre-clinically, I'd say it appears outstanding. Then naturally, we hold considerable trust in the USP platform, which we've studied thoroughly throughout our registration program for the Ebola virus vaccine. So I've been monitoring both; and I believe they could be rather significant.

Ken Frazier

executive
#33

Thanks. Lauer, you're up next. We'll get that sorted out, so we can squeeze in as many questions as we can. Thanks.

Seamus Fernandez

analyst
#34

Many thanks; Roger, I wanted to ask a follow-up regarding EIDD-2801, or Merck’s newly assigned designation MK-4482. More importantly, though, when considered as a possible therapy for additional respiratory retroviruses, could you help us grasp whether you think it might work in those situations, and whether this mechanism could have wider potential? Then, secondly, I actually wanted to inquire about your HIV program, MK-8591. My understanding is that Merck had been hoping for a second agent to pair with MK-8591 so as to maximize the treatment opportunity. Could you perhaps bring us up to date on that, in the setting of finding a longer-acting treatment regimen? And then, separately, concerning how robust the data are for certain other agents in the prep regimen, maybe you could just share your current thinking on MK-8591 as a possible best-in-class treatment option for prep? Thanks.

Ken Frazier

executive
#35

Go ahead, Roger.

Roger Perlmutter

executive
#36

Yes, Seamus, I appreciate those questions. When it comes to MK-4482, you're correct — entirely correct — that due to the way it works, it looks like a nucleoside base. In fact, it's simply a derivatized form of a cytosine; any newly forming RNA strand produced by a suitable virus can take it in; whether that happens depends purely on how readily the viral polymerase accepts this modified base. And as anyone would anticipate, since a virus is designed for speed, generally speaking the RNA polymerases of RNA viruses tolerate varying structures more easily than the mammalian DNA-dependent RNA polymerases that our bodies use to produce messenger RNA, for instance. Consequently, it has favorable selectivity and favorable characteristics in that respect, and ought to perform quite effectively across a wide range of RNA viruses in vitro — which is precisely what it does. Thus an entire collection of RNA viruses might potentially be addressed, encompassing, in broad terms, coronaviruses with which we have not yet become familiar. We certainly don't wish to become familiar with them, but our expectation is that this won't be our final pandemic and likely won't be the final pandemic brought about by a coronavirus; therefore MK-4482 possesses broad activity and may prove useful across many different situations. Let's begin by seeing how it performs against SARS-CoV-2. As for islatravir, we have — naturally, we continue to be tremendously excited about islatravir. Phase 3 trials are underway for the initial group of combinations involving islatravir for treating people infected with HIV. And we have also, as you mentioned, been searching for compounds to pair with islatravir, and we possess such compounds. One that is advancing at present is MK-8507. And we have a set of additional ones too. So we feel we're in a solid position regarding those. Yet we're progressing along many different paths. And then concerning pre-exposure prophylaxis, yes, since islatravir lasts such a long time, the possibility of a once-monthly oral option in particular, which might be deployed anywhere on the planet, strikes me as very appealing. But past that, as we've demonstrated, islatravir is able to be formulated into an implantable version, which is a polymer placed beneath the skin and can remain active for perhaps a year. And that delivers something approaching the closest thing to ideal chemoprophylaxis that one could achieve — it's almost comparable to a vaccine. So we're chasing that too, and we're hopeful about islatravir's capacity to bring about a major shift regarding how widespread HIV-mediated disease is and how often HIV infection occurs.

Ken Frazier

executive
#37

Thank you, Seamus. Next question, please, Laura.

Daina Graybosch

analyst
#38

I appreciate the question, and I have two for you. First, what makes you so sure that both of your COVID vaccine candidates can work as just one shot, given that, for instance, the chimpanzee adenovirus vector—which, as I recall, we also believed would need only a single dose—appears far more effective with two doses based on the initial clinical results? And my second question, building on one asked previously: as clinical data comes in, do you intend to pick one of the two vaccine programs, or is your expectation to advance both all the way to registration, perhaps positioning them differently in the marketplace? Thanks.

Ken Frazier

executive
#39

Roger?

Roger Perlmutter

executive
#40

Absolutely, I appreciate those questions. We’re quite optimistic about the single-dose effect from both of these vaccines, since they are replicating vaccines. They multiply within the body, making them highly effective immunogens, and they’ve shown single-dose, single-administration effectiveness in other contexts. With V590, for instance—that’s the vesicular stomatitis virus vaccine—this has been very effectively demonstrated for Ebola virus disease. In real-world conditions during large-scale civil unrest, one dose achieved over 97.5% efficacy. Now, I can’t guarantee it will act the same way when we insert a different gene—in this case, the SARS-CoV-2 spike protein, with nucleic acids encoding the spike protein—into the construct. But what’s fascinating about the VSV platform is that the spike protein actually becomes a component of the vaccine itself; the virus’s replication is entirely reliant on the spike protein, which becomes the envelope protein—this sets it apart from merely expressing the protein somewhere else. That makes a significant difference. And in preclinical studies, the scale of the response after a single dose is very striking. Likewise, the measles platform has proven to be a strong immunogen in many different scenarios, most recently with chikungunya administration; we have substantial expertise there. As for Y2, like I mentioned, there’s good reason to think that multiple vaccines will be necessary to handle this unprecedented global pandemic. Especially when you consider how diverse the population we need to vaccinate is—those with very strong immune reactions, like teenagers or people in their 20s, versus the elderly who are at highest risk but often have weaker immune responses, just to offer a few examples. There’s also the matter of being able to deliver the vaccine to various regions worldwide and successfully administer it within a massive global vaccination effort. So right now, our plan isn’t to pick one, but rather to study the unique characteristics of each of these strong platforms and then determine which should be prioritized first, for which group, and which maybe second—though both could move forward at the same time.

Ken Frazier

executive
#41

Appreciate that, Daina. There's time for one final question, and to everyone we weren't able to reach today, you have our apologies.

Chris Schott

analyst
#42

Okay, great. I really appreciate you taking the questions. There are just a few things I want to ask. The first one concerns KEYTRUDA — at this stage, would you say new patient starts look pretty much normal in the major markets, or are there still some disruptions occurring there? And perhaps that ties into the same answer, but could you quickly bring us up to date on roughly where market share and penetration sit in frontline lung? Then my second question relates to the vaccine business and wellness visits. As we get into July now, are we likewise at normal levels? Do you expect any catch-up later in the year for some of the vaccinations that were missed in 2Q? Many thanks.

Ken Frazier

executive
#43

Frank?

Frank Clyburn

executive
#44

Yes, Chris, good morning. Regarding Keytruda, we're quite optimistic, particularly during the past month; we're observing new patient starts returning to nearly the pre-COVID levels. If you examine what occurred during the quarter, Chris, new patient starts in April and May declined somewhere in the range of roughly 5% to 10%, varying by cancer type, though that situation has gotten better. And we're witnessing this essentially across the globe, where oncologists are now determining methods to bring patients into their clinics. That will differ by geography. There will be some fluctuations surrounding it, yet overall oncology has proven quite resilient. And probably most significantly, what gives us encouragement is the ongoing robust momentum, not just in non-small cell lung cancer, where we continue to observe in the U.S. initially around 80% of eligible patients getting Keytruda; but we're also quite thrilled about all the additional indications Roger referenced, and we're witnessing genuinely solid growth in head and neck, bladder, adjuvant melanoma, along with some of the other more recent indications. So overall, we feel quite confident in Keytruda not just in the near term, but as we've kept staying long-term concerning vaccines, you heard from Rob's remarks at the beginning that April and May wellness visits dropped very substantially, particularly in the U.S. market, approximately 70% during the month of April. They began to get better by the time you reached June; and we truly saw some encouraging pickup with wellness visits for our pediatric portfolio and for the pediatric patient population. Adolescents are trailing somewhat behind, which is why we noted we're keeping watch on GARDASIL, but we are seeing encouraging signals there with wellness visits, improving as well, which provides us the confidence, not only near term for GARDASIL, but as we stated, the strong demand that we continue to believe will materialize for GARDASIL, not only in the U.S.; but clearly outside the U.S.; in markets, such as China, so very confident in that outlook as well, Chris.

Peter Dannenbaum

executive
#45

Great, thank you Chris. I’ll turn to Ken for closing comments.

Ken Frazier

executive
#46

Appreciate that, Peter. From what you've heard during this session, our confidence hasn't wavered when it comes to the strategy we're pursuing, how we're carrying it out, and what lies ahead in terms of robust growth over the long haul. On top of that, we're still dedicated to making Merck's mission a reality — speaking up for creative solutions and collaborative efforts that are going to be crucial in putting a stop to this pandemic — all while continuing to put money behind our pipeline, which holds a lot of promise. My thanks go out to each of you for being here with us today. And my hope is that you, along with your loved ones, remain safe and well.

Operator

operator
#47

Much appreciated, sir. Many thanks to the presenters; and once more, thanks to all of you for joining in. That brings today's call to a close. You're welcome to hang up now. Take care and enjoy the rest of your day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Merck & Co., Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Merck & Co., Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck & Co., Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.